Claims for Patent: 8,236,799
✉ Email this page to a colleague
Summary for Patent: 8,236,799
Title: | Biaryl compositions and methods for modulating a kinase cascade |
Abstract: | The invention relates to compounds and methods for modulating one or more components of a kinase cascade. The invention relates to compounds of the formula I: ##STR00001## or a pharmaceutically acceptable salt thereof. The compounds of the invention are useful for methods of protecting against or treating hearing loss, osteoporosis, cell proliferative disorders, obesity, diabetes, eye disease, stroke, atherosclerosis, neuropathic pain or hepatitis B. |
Inventor(s): | Hangauer, Jr.; David G. (Lancaster, NY) |
Assignee: | Kinex Pharmaceuticals, LLC (Buffalo, NY) |
Application Number: | 13/152,949 |
Patent Claims: |
1. A compound according to Formula IA ##STR00400## or a pharmaceutically acceptable salt thereof, wherein: T is a bond; X.sub.y is N; X.sub.z is CZ; X.sub.a is CR.sub.a or
N; X.sub.b is CR.sub.b; X.sub.c is CR.sub.c; X.sub.d is CR.sub.d; X.sub.c is CR.sub.e; R.sub.a is hydrogen; R.sub.b is O-lower (C.sub.1, C.sub.2, C.sub.3, C.sub.4, C.sub.5, or C.sub.6) alkyl-aryl, ##STR00401## wherein W is H or (C.sub.1, C.sub.2,
C.sub.3, C.sub.4, C.sub.5, or C.sub.6) alkyl; V is a bond or --OCH.sub.2CH.sub.2--; R.sub.c and R.sub.5 are, independently, hydrogen, (C.sub.1, C.sub.2, C.sub.3, C.sub.4, C.sub.5, or C.sub.6) alkyl or halogen; R.sub.d, R.sub.e and R.sub.4 are
hydrogen; Z is ##STR00402## wherein R.sub.1, R.sub.2, and R.sub.3 are, independently, hydrogen or (C.sub.1, C.sub.2, C.sub.3, C.sub.4, C.sub.5, or C.sub.6) alkyl; R.sub.7 and R.sub.11 are selected from hydrogen, (C.sub.1, C.sub.2, C.sub.3, C.sub.4,
C.sub.5, or C.sub.6) alkoxy and O-benzyl; R.sub.8 and R.sub.10 are selected from hydrogen and halogen; R.sub.9 is hydrogen; n is 1; and m is 1.
2. The compound of claim 1, wherein one of R.sub.7 and R.sub.11 is (C.sub.1, C.sub.2, C.sub.3, C.sub.4, C.sub.5, or C.sub.6) alkoxy or O-benzyl and the other is hydrogen. 3. The compound of claim 2, wherein R.sub.7 or R.sub.11 is C.sub.2 alkoxy. 4. The compound of claim 2, wherein R.sub.7 or R.sub.11 is O-benzyl. 5. The compound of claim 1 according to Formula II or III: ##STR00403## or a pharmaceutically acceptable salt thereof; wherein R.sub.b is ##STR00404## wherein W is hydrogen or (C.sub.1, C.sub.2, C.sub.3, C.sub.4, C.sub.5, or C.sub.6) alkyl; R.sub.4 is hydrogen; R.sub.5 is (C.sub.1, C.sub.2, C.sub.3, C.sub.4, C.sub.5, or C.sub.6) alkyl or halogen; and R.sub.8 and R.sub.10 are, independently, hydrogen or halogen. 6. The compound of claim 5 wherein the compound is a compound of formula II. 7. The compound of claim 6 wherein R.sub.5 is C.sub.1 or C.sub.2 alkyl. 8. The compound of claim 6 wherein R.sub.5 is fluoro or chloro. 9. The compound of claim 1, wherein the compound is selected from ##STR00405## ##STR00406## ##STR00407## ##STR00408## 10. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient. 11. A pharmaceutical composition comprising a compound of claim 9 or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient. 12. The compound of claim 1, wherein R.sub.b is O-lower (C.sub.1, C.sub.2, C.sub.3, C.sub.4, C.sub.5, or C.sub.6) alkyl-aryl or ##STR00409## 13. The compound of claim 12, wherein aryl is tetrazole. 14. The compound of claim 12, wherein V is a bond. 15. The compound of claim 1, wherein R.sub.5 is halogen. 16. The compound of claim 15, wherein halogen is fluoro. |